These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Sexual variations in the metabolism of antipyrine in vivo and in vitro]. Salvá P; Salvá JA; Laporte J Arch Farmacol Toxicol; 1978 Apr; 4(1):116-9. PubMed ID: 697376 [No Abstract] [Full Text] [Related]
27. [Influence of fasting on antipyrine hydroxylation]. Liébecq C Arch Int Pharmacodyn Ther; 1965 Sep; 157(1):219-23. PubMed ID: 5885801 [No Abstract] [Full Text] [Related]
28. Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women. Homeida M; Halliwell M; Branch RA Clin Pharmacol Ther; 1978 Aug; 24(2):228-32. PubMed ID: 679600 [TBL] [Abstract][Full Text] [Related]
29. Hepatic mixed function oxidase induction during rifampicin/isoniazid therapy in Indian vegetarians. Perry W; Jenkins MV Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):344-8. PubMed ID: 3733284 [TBL] [Abstract][Full Text] [Related]
30. [Effect of varying vitamin D status in the body on intestinal absorption and metabolism of vitamin D in the rat liver]. Apukhovskaia LI; Khrestovaia NL; Antonenko LV; Omel'chenko LI; Dotsenko LA Ukr Biokhim Zh (1978); 1990; 62(6):88-92. PubMed ID: 1965073 [TBL] [Abstract][Full Text] [Related]
31. The features of hepatic enzyme induction with glutethimide in man. Jackson L; Homeida M; Roberts CJ Br J Clin Pharmacol; 1978 Dec; 6(6):525-8. PubMed ID: 728322 [TBL] [Abstract][Full Text] [Related]
32. [Vitamin D: influence of anticonvulsant drugs on its metabolism]. Gascon Barré M Union Med Can; 1977 May; 106(5):636-41. PubMed ID: 325851 [No Abstract] [Full Text] [Related]
33. Salivary antipyrine half-life: a useful measure of hepatic drug metabolism. Brooks PM; Bell MA; Burns H Br J Clin Pharmacol; 1976 Oct; 3(5):945-6. PubMed ID: 973995 [No Abstract] [Full Text] [Related]
34. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease. Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397 [TBL] [Abstract][Full Text] [Related]
35. Drug metabolism in uremia. Reidenberg MM Clin Nephrol; 1975; 4(3):83-5. PubMed ID: 1102176 [No Abstract] [Full Text] [Related]
36. Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Ohnhaus EE; Kirchhof B; Peheim E Clin Pharmacol Ther; 1979 May; 25(5 Pt 1):591-7. PubMed ID: 35298 [No Abstract] [Full Text] [Related]
37. Lack of effect of subclinical ascorbic acid deficiency upon antipyrine metabolism in man. Holloway DE; Hutton SW; Peterson FJ; Duane WC Am J Clin Nutr; 1982 May; 35(5):917-24. PubMed ID: 7081090 [TBL] [Abstract][Full Text] [Related]
39. Saliva and plasma clearance of antipyrine as reflectors of liver function. Luoma PV; Sotaniemi EA Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326 [TBL] [Abstract][Full Text] [Related]
40. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination]. Soto Alvarez J; Alsar Ortiz MJ Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]